The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear - Loren, C P; Aslan, J E; Rigg, R A (Thromb Res, 2015)
, et al.